Employers are finding themselves between a rock and hard place when it comes to health benefits. If they reduce or eliminate benefits, they lose quality workers as well as productivity. If they maintain or increase benefits, they're almost certain to spend beyond their budgets year after year. In trying to strike a happy medium, more employers are now remodeling their health benefit plans dramatically, hoping to see better results.
"I've always believed that the end game is to improve health and reduce the overall cost burden as opposed to trying to shift costs," Critelli says. "Let's say you're successful with shifting health plan costs to the employee, what you would find, and what many companies have found, is that they simply get a lot more worker's comp claims."
As the chief personnel officer in the 1990s, Critelli witnessed the problem of high healthcare spending for this self-insured company. A progressive remodeling of its benefit approach and the institution of a healthier corporate culture eventually led Pitney Bowes to where it is now: cost trends that are 33% lower compared with similar employers. The organization invests $150 million annually in health, and that 33% difference is a substantial advantage.
"We moved rather rapidly from zero cost sharing to 20%, and we wanted to give people something in return," Critelli says. "That's when we started [on-site] health clinics, preventive screenings and active case management, and tried to present a more caring face to employees as were asking them to spend more out-of-pocket dollars on health."
He says it was important to prevent the perception that the company was only taking away benefits and not giving anything new, something many employers fail to recognize when reworking benefit plans.
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen